Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

Organicell Announces FDA Approval Of IND Application For The Use Of Zofintm In The Treatment Of Osteoarthritis


Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofintm, in the treatment of knee osteoarthritis.

This approved trial design, which will begin in the second quarter of this year, will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of Zofintm for patients suffering with knee osteoarthritis.

Zofintm is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues.

According to the Centers for Disease Control and Prevention, osteoarthritis (OA) is the most common form of arthritis and affects over 32 million adults in the US. It occurs most frequently in the hands, hips, and knees, where the cartilage within the joints begin to break down and the underlying bones begin to change. It is a chronic disease, and these changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling, and in some cases, causes reduced function and disability; some people are no longer able to do daily tasks or work.

"Osteoarthritis is a very common, degenerative disease with no cure or long-term treatment strategy," said Dr. Mari Mitrani, Chief Science Officer of Organicell. "We are excited to initiate this FDA approved clinical trial and to further explore the potential of Zofintm in battling this disease."

About Zofintm:

Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin for the treatment of moderate to SARS related to COVID-19 infection.

ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

FORWARD-LOOKING STATEMENTS

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.


These press releases may also interest you

at 07:06
The federal government has approved billions of dollars of relief funds for schools, but some educators are unclear where the funds originate and how they should be used. Today, OverDrive Education announced a new effort to guide school districts...

at 07:05
Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. , a leading global game company, announced that its PC game Dragon Saga has returned to the European regions as of May 12, 2021, including Switzerland, Norway, the UK, and Turkey. Dragon...

at 07:05
Argo Blockchain Plc (LSE: ARB) , a UK-based global cryptocurrency mining company, and DMG Blockchain Solutions Inc. , a vertically integrated blockchain and cryptocurrency technology company, today announced their partnership with the Crypto Climate...

at 07:05
Forma Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today reported financial results for the first quarter ended March 31, 2021. The company also highlighted recent progress...

at 07:05
RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodevelopmental function from patients in Cohorts 1 and 2 continue to indicate CNS activity...

at 07:03
The Web Excellence Awards, a leading international interactive web awards competition, has announced the 2021 award winners to highlight this year's "best of the best" in web design and development. Biofriendly, the leading green solutions company,...



News published on 21 april 2021 at 07:35 and distributed by: